A practical note on turning regulatory preparation into traceable sprint evidence.
5 min read
For: medtech founders, product teams, software teams, and regulatory leads building software-enabled medical devices or SaMD products.
<aside> 💡
CE and MDR readiness should not start when the product is "almost done".
By then, the evidence chain is already fragmented.
For software-enabled medical devices and SaMD products, the stronger approach is to connect regulatory preparation directly to the sprint rhythm.
</aside>
MDR is not only about the document package prepared at submission time. It expects the evidence chain to stay current across the device lifecycle.
That means classification, risk management, software lifecycle evidence, clinical evaluation, technical documentation, and post-market surveillance should be managed as connected parts of the same system.
Sprint-based readiness reduces the risk of:
The device class determines the conformity assessment route and the expected depth of evidence. For software-enabled products, this decision needs particular care. If software affects clinical decisions, diagnosis, therapy, or physiological monitoring, the risk class may be higher than the team's first assumption.